Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

Glutamatergic Modulation to Facilitate Naltrexone Initiation: A randomized, controlled trial
Medication-Assisted Therapeutic Treatment Research for Opioid Use
Sponsor:NIDA
Enrolling:Male and Female Patients
Study Length:13 Weeks
Age Range:Between 18 and 70 years old
IRB Number:7543
U.S. Government ID:NCT03345173
Contact: HOPE Clinic: 888.497.8427 / dakwarlab@nyspi.columbia.edu
Additional Study Information:

This free and confidential study is recruiting healthy adults who are currently seeking treatment for opioid use (heroin, painkillers). Participants will be admitted into our inpatient unit for the first 3 to 5 days of the study. In addition to traditional medications used during detoxification, you will also receive innovative, investigative medications that may help with the transition onto Vivitrol (extended-release nalrexone). After discharge from the inpatient unit, participants will engage in twice-weekly outpatient visits for 12 weeks. These visits involve therapy sessions, meeting with a study physician, and completing measures with research assistants. Participants will receive a total of 3 Vivitrol shots throughout the study and will be referred to a community Vivitrol provider once they have completed.

Do You Qualify?
Are opioids (heroin or painkillers like Percocet, Oxy, etc.) a problem for you?YesNo
Are you seeking treatment for your opioid use?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
HOPE Clinic
Email: dakwarlab@nyspi.columbia.edu
Phone: 888.497.8427